Genomic Health, NCCN, NIH, Third Wave Technologies, Craig Venter, DiaGenic, Harvard Medical School, Michael J. Fox Foundation, Qiagen, Ventana | GenomeWeb
Genomic Health's Breast Cancer Test Listed in NCCN's Guidelines
 
Genomic Health said this week that its predictive breast cancer assay has been included in the National Comprehensive Cancer Network’s 2008 Breast Cancer Treatment Guidelines.
 
The company’s Oncotype DX is a multi-gene expression test used to predict the chances of breast cancer recurrence and the likelihood that chemotherapy will benefit certain patients, the company said.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.